WO2014155268A3 - Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity - Google Patents

Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity Download PDF

Info

Publication number
WO2014155268A3
WO2014155268A3 PCT/IB2014/060087 IB2014060087W WO2014155268A3 WO 2014155268 A3 WO2014155268 A3 WO 2014155268A3 IB 2014060087 W IB2014060087 W IB 2014060087W WO 2014155268 A3 WO2014155268 A3 WO 2014155268A3
Authority
WO
WIPO (PCT)
Prior art keywords
activity
snf5
lack
inhibitors
fgf
Prior art date
Application number
PCT/IB2014/060087
Other languages
French (fr)
Other versions
WO2014155268A2 (en
Inventor
Diana Graus Porta
Simon Woehrle
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2014155268A2 publication Critical patent/WO2014155268A2/en
Publication of WO2014155268A3 publication Critical patent/WO2014155268A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FGF-R tyrosine Kinase Activity Inhibitors useful in Case of Lack of SNF5 Activity. The invention relates to the use of FGF-R inhibitors in the (prophylactic and/or therapeutic) treatment of proliferative diseases that depend on at least partial lack of SNF5 activity, the use of said inhibitors for the preparation of a pharmaceutical composition (medicament) for said use, said inhibitors for use in a method of (therapeutic and/or prophylactic) treatment of a proliferative disease depends on at least partial lack of SNF5 activity, a method of (prophylactic and/or therapeutic) treatment of a proliferative disease that depends on at least partial lack of SNF5 activity and a pharmaceutical composition (medicament) for use in the (prophylactic and/or therapeutic) treatment of a proliferative disease that depends on at least partial lack of SNF5 activity, as well as related invention embodiments.
PCT/IB2014/060087 2013-03-25 2014-03-24 Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity WO2014155268A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361804797P 2013-03-25 2013-03-25
US61/804,797 2013-03-25

Publications (2)

Publication Number Publication Date
WO2014155268A2 WO2014155268A2 (en) 2014-10-02
WO2014155268A3 true WO2014155268A3 (en) 2014-12-04

Family

ID=50483186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/060087 WO2014155268A2 (en) 2013-03-25 2014-03-24 Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity

Country Status (1)

Country Link
WO (1) WO2014155268A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112877425A (en) * 2021-04-22 2021-06-01 宁夏医科大学 Application of reagent for detecting SNF5 gene expression in preparation of atherosclerosis diagnosis product

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (en) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Ring gap magnet system
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
RO119721B1 (en) 1992-10-28 2005-02-28 Genentech Inc. Antagonists of vascular endotelial cell growth factor
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE122005000053I2 (en) 1995-03-30 2008-01-17 Pfizer Prod Inc quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EA001428B1 (en) 1995-07-06 2001-02-26 Новартис Аг Pyrrolopyrimidines and pharmaceutical compositions
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN1145614C (en) 1996-04-12 2004-04-14 沃尼尔·朗伯公司 Irreversible inhibitors of tyrosine kinases
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
DE19638745C2 (en) 1996-09-11 2001-05-10 Schering Ag Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (en) 1997-02-13 2000-09-01 Novartis Ag PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
DE69942097D1 (en) 1998-08-11 2010-04-15 Novartis Ag ISOCHINOLINE DERIVATIVES WITH ANGIOGENESIS-HEMMENDER EFFECT
UA71587C2 (en) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Anthranilic acid amides and use thereof as medicaments
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
EP1140173B2 (en) 1998-12-22 2013-04-03 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
ATE329596T1 (en) 1999-03-30 2006-07-15 Novartis Pharma Gmbh PHTHALAZINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
AR079257A1 (en) 2009-12-07 2012-01-04 Novartis Ag CRYSTAL FORMS OF 3- (2,6-DICLORO-3-5-DIMETOXI-PHENYL) -1- {6- [4- (4-ETIL-PIPERAZIN-1-IL) -PENYL-AMINO] -PIRIMIDIN-4- IL} -1-METHYL-UREA AND SALTS OF THE SAME

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Final report: Therapeutically targeting aberrant chromatin remodeling in sarcomas (Project Number: SFA09-20)", 1 February 2011 (2011-02-01), XP002726892, Retrieved from the Internet <URL:https://www.curesarcoma.org/documents/uploads/Roberts_Final_Report.pdf> [retrieved on 20140709] *
KLENKE F M ET AL: "Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo", BMC CANCER, vol. 7, 17 March 2007 (2007-03-17), XP002123128, ISSN: 1471-2407 *
KONECNY GOTTFRIED E ET AL: "Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells", MOLECULAR CANCER THERAPEUTICS, vol. 12, no. 5, 26 February 2013 (2013-02-26), pages 632 - 642, XP002726890 *
LOCH DAVID C ET AL: "Lineage-Specific Biomarkers Predict Response to FGFR Inhibition", CANCER DISCOVERY, vol. 2, no. 12, December 2012 (2012-12-01), pages 1081 - 1083, XP002726889 *
WÖHRLE SIMON ET AL: "Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.", PLOS ONE, vol. 8, no. 10, E77652, 30 October 2013 (2013-10-30), pages 1 - 11, XP002726891, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0077652 *

Also Published As

Publication number Publication date
WO2014155268A2 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
WO2012062925A3 (en) Compounds and methods for treating pain
MY169987A (en) Selective pi3k delta inhibitors
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
WO2013012915A8 (en) Heterocyclic compounds and uses thereof
MX2020009780A (en) Autotaxin inhibitor compounds.
SG10201902074UA (en) Heterocyclic compounds and uses thereof
BR112015003397A2 (en) compound, pharmaceutical composition, use of the compound and method for treating a rorgammat-mediated disease or condition in a patient.
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
CL2014000849A1 (en) Compounds derived from substituted benzylindazoles, bub1 kinase inhibitors; manufacturing procedure; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of hyperproliferative diseases.
MX2015010791A (en) Methods of treating cancer and preventing drug resistance.
PH12015502698A1 (en) Dual selective pi3 delta and gamma kinase inhibitors
MX2016002580A (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases.
MX2021010041A (en) Pharmaceutical compositions comprising akt protein kinase inhibitors.
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
WO2012125981A3 (en) Raf kinase inhibitors
WO2014121137A3 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
EP3337482A4 (en) Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
EP2991733A4 (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
IN2014DN09240A (en)
WO2014138616A3 (en) Pyrazole compounds and methods of use thereof
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
PH12017501979A1 (en) Pharmaceutical compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14717079

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14717079

Country of ref document: EP

Kind code of ref document: A2